Search results
Results from the WOW.Com Content Network
Microsoft Intune (formerly Microsoft Endpoint Manager and Windows Intune) is a Microsoft cloud-based unified endpoint management service for both corporate and BYOD devices. [2] It extends some of the "on-premises" functionality of Microsoft Configuration Manager to the Microsoft Azure cloud.
A regional lockout (or region coding) is a class of digital rights management preventing the use of a certain product or service, such as multimedia or a hardware device, outside a certain region or territory.
Mobile device management (MDM) is the administration of mobile devices, such as smartphones, tablet computers, and laptops.MDM is usually implemented with the use of a third-party product that has management features for particular vendors of mobile devices.
User Interface Privilege Isolation (UIPI) is a technology introduced in Windows Vista and Windows Server 2008 to combat shatter attack exploits. By making use of Mandatory Integrity Control, it prevents processes with a lower "integrity level" (IL) from sending messages to higher IL processes (except for a very specific set of UI messages).
Geo-blocking can be circumvented.When IP address-based geo-blocking is employed, virtual private network (VPN) and anonymizer services can be used to evade geo-blocks. A user can, for example, access a website using a U.S. IP address in order to access content or services that are not available from outside the country.
Ad blockers insert code into your browser to block ads, which can negatively impact website performance, break functionality, and even hide messages in AOL Mail. We recommend unblocking AOL Mail websites to avoid facing these issues. Doing this will also unblock ads. Adjust Other settings
As a time-limited promotion, Microsoft stated that this upgrade would be free on the Surface Laptop until March 31, 2018. [202] Windows 10 S also contains a faster initial setup and login process, and allows devices to be provisioned using a USB drive with the Windows Intune for Education platform.
(Reuters) -Regeneron Pharmaceuticals said on Monday the U.S. FDA has declined approval for its blood cancer therapy for two forms of lymphoma on concerns over the progress of ongoing confirmatory ...